Privately-held Californian firm Alladapt Immunotherapeutics has announced top-line results from the Phase I/II Harmony study of its multi-targeted allergy treatment ADP101.
Interest in food allergies has grown since the approval of peanut allergy medicine Palforzia (peanut allergen powder) and subsequent purchase of developer Aimmune Therapeutics (Nasdaq: AIMT) by Nestle for $2.6 billion.
However, with much slower-than-expected takeup, Palforzia has become, by Nestle’s own admission, a niche product rather than a blockbuster.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze